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SPAG5 is a mitotic spindle protein. Recent studies have found that it is overexpressed in many 
human cancers and functions as an oncogene. We summarize the current underlying 
mechanisms for its oncogenic roles in regulating cellular behaviors of cancer cells and discuss 
the possibility to target SPAG5 for cancer treatment. 
 
 
SPAG5 in human cancers 
Sperm associated antigen 5 (SPAG5, also called astrin) is a mitotic spindle protein. In normal 
cells, it ensures a correct separation of sister chromatids into daughter cells. SPAG5 depletion 
induces a spindle checkpoint arrest characteristic of the formation of multipolar spindles and a 
loss of sister chromatid cohesion [1]. However, SPAG5 gene gains and amplifications are 
observed in many cancers (Table 1). Increased SPAG5 expression is correlated with poor 
clinical outcomes and adverse clinicopathological features in breast cancer [2]. In several 
cancer models, SPAG5 is implicated in neoplastic growth, chemoresistance, metastasis, local 
recurrence and overall survival, whereas its downregulation results in suppressed cell 
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proliferation, impaired migration motility and enhanced apoptosis and chemosensitivity [2-7]. 
In addition, SPAG5 can be used as an antigen for cancer vaccine development [8]. These 
observations clearly indicate that SPAG5 is a novel driver oncogene and may be a therapeutic 
target. Herein, we summarize the current signaling pathways that are regulated by SPAG5 and 
those that mediate the cellular functions of SPAG5 in cancer cells and propose a strategy to 
target SPAG5 for cancer therapy. 
 
SPAG5 Signaling in Cancer 
Compelling evidence has demonstrated that SPAG5 is involved in various intracellular 
processes that regulate tumor initiation and progression, in addition to counteracting the 
cytotoxic effects of many chemotherapies. 
Oxidative stress is a prevalent condition in tumors. The mammalian target of rapamycin 
(mTOR) complex 1 (mTORC1) is activated in response to stress and promotes the biosynthesis 
of stress response proteins. Upon metabolic challenge and oxidative stress, the deprivation of 
tuberous sclerosis proteins 1 and 2 (TSC1-TSC2) activates mTORC1 and upregulates SPAG5 
levels. In addition to mitosis-related functions, SPAG5 inhibits mTOR-raptor association and 
recruits raptor to stress granules (SGs), inhibiting mTORC1 activity (Figure 1A). Thus, TSC1-
TSC2 combined with SPAG5 keep the cellular level of mTORC1 under control. This balanced 
mTORC1 activity enables expression of stress response proteins that are required for cell 
survival under stress, and prevents cells from undergoing mTORC1 hyperactivation-induced 
apoptosis [9]. However, hyperactivation of mTORC1 induced by lack of functional SPAG5 
may increase hypoxia tolerance by promoting the biosynthesis of hypoxia-inducible factor 1α 
(HIF-1α) in cancer cells [10], and autophagy by phosphorylating autophagy regulatory 
complex containing unc-51-like kinase 1 (ULK1), the mammalian ATG13 protein and focal 
adhesion kinase interacting protein of 200 kDa (FIP200) [11]. Further studies are required to 
investigate to what extent SPAG5-mediated hyperactivation of mTORC1 influences autophagy 
and hypoxia tolerance in cancer cells in the absence of functional SPAG5.  
SPAG5 is also found to prohibit apoptosis through the p53-mediated DNA damage 
response pathway, which modulates cellular responses to DNA damage, redox stress, or 
abnormal oncogene amplification, and promotes several pro-apoptotic genes, such as, BAX, 
PUMA, and NOXA (Figure 1A). Upon genotoxic stresses, upregulated p53 induces BAX 
expression and elevated caspase-3 activity in the absence of functional SPAG5 [12]. The 
upregulation of p53 also inhibits mTORC1 activity via the TSC1-TSC2 complex, leading to 
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interference in protein synthesis [12]. Thus, in tumor cells overexpression of SPAG5 coupled 
with suppression of p53 result in an environment favoring cell growth and proliferation when 
challenged with DNA lesions. 
Secreted Wnt3 protein plays an oncogenic role in cancers. SPAG5 upregulates Wnt3 
by activating the AKT/mTOR signaling (Figure 1B) [7]. Accordingly, cancer cells 
overexpressing SPAG5 that are adequate in Wnt3 expression display elevated levels of cell 
proliferation, invasion and chemoresistance even after exposure to agents that induce cell cycle 
arrest [13]. This pro-proliferative effect is due to the dephosphorylation of β-catenin induced 
by ligand binding of Wnt3. β-catenin is able to translocate into the nucleus in its 
dephosphorylated state and form a complex with T cell factor (TCF), which can activate gene 
transcription, including of oncogenes. This canonical Wnt3/β-catenin signaling pathway can 
transactivate the expression of epidermal growth factor receptor (EGFR), which is related to 
chemoresistance to trastuzumab in human epidermal growth factor receptor 2 (HER2) 
overexpressing breast cancer cells [13]. It also confers resistance to the chemodrug cisplatin in 
bladder cancer [7]. Furthermore, the translocation of β-catenin plays a significant role in 
regulating epithelial-mesenchymal transition [13]. The transition could promote not only tumor 
invasion and metastases, but also resistance to tamoxifen in estrogen receptor positive breast 
cancer cell lines. 
Centrosome protein 55 (Cep55) helps physical separation of dividing cells in the final 
stage of the cell cycle, a process called cytokinesis. Recent work demonstrated that Cep55 
facilitates cell proliferation and migration through activation of PI3K/AKT/mTOR pathway. 
SPAG5 enhances this promoting effect by its binding to Cep55 (Figure 1C). In normal healthy 
cells, balanced expression of SPAG5 mediates Cep55, making cell division and proliferation 
controllable. In tumor cells, however, the overexpression of SPAG5 makes this protein-protein 
interaction detrimental since it stimulates activation of many downstream effectors that favor 
cell proliferation and survival [14]. 
The scavenger receptor class A member 5 (SCARA5) is a tumor suppressor gene that 
suppresses progression and metastasis of cancer. Converging evidence shows that SCARA5 
expression is frequently downregulated in cancer cells, and suppression of SPAG5 leads to a 
rise in SCARA5 levels, which in turn, slows down cell progression and promotes apoptosis 
(Figure 1D). It is proposed that SPAG5 downregulates SCARA5 expression via activation of 
the β-catenin/TCF4 pathway. As aforementioned, SPAG5 can typically result in 
dephosphorylation and translocation of β-catenin through the AKT/mTOR/Wnt axis. In 
combination with TCF4, degraded β-catenin further mediates gene transcription, thereby 
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downregulating SCARA5 expression. Thus, the proliferation of cancer cells with aberrant 
SPAG5 expression is accelerated due to the role played by SPAG5 in SCARA5 downregulation 
[6]. 
Emerging evidence demonstrates that SPAG5 may confer resistance to olaparib in 
triple-negative breast cancer (Figure 1E) [3]. c-MYC is a crucial oncogenic transcription factor 
mediating gene transcription that is involved in multiple cellular mechanisms, such as cell 
proliferation, cell apoptosis, cell-cycle control, and DNA repair. SPAG5 can enhance the 
transcriptional activity of c-MYC through increasing and interacting with c-MYC binding 
protein (MYCBP). c-MYC could then directly upregulate the expression of homologous 
recombination (HR) DNA repair proteins RAD51, BRCA1 and BRCA2, which confer 
resistance to olaparib by repairing the DNA lesions due to inhibited poly-ADP ribose 
polymerase (PARP) activity. Another mechanism through which SPAG5 confers resistance to 
olaparib is through mediating the cell cycle. SPAG5 promotes S/G2 transition, leading to a 
reduced S-phase duration in which olaparib-provoked DNA lesions occur. Therefore, SPAG5 
may be used as a potential biomarker to stratify patients for olaparib treatment [3]. 
In summary, SPAG5 modulates cell proliferation and migration/metastasis through the 
activation of the PI3K/AKT/mTOR pathway and its downstream effectors such as Wnt 
signaling. SPAG5 also affects cell growth and apoptosis by downregulating p53 and mTORC1 
signaling and upregulating c-MYC signaling. As a result of decreased cell death and increased 
proliferation, cancer cells become more resistant to chemodrugs. 
 
Upstream Regulators of SPAG5 
SPAG5 is regulated by many upstream regulators, including glycogen synthase kinase 3β 
(GSK3β), human Ninein (hNinein), Aurora B kinase, OSBP-related protein 8 (ORP8), p29, 
sensitive to nitrogen mustard 1A (SNM1A), and Mid2 ubiquitin ligase. A few studies have 
reported the oncogenic functions of SPAG5 are mediated by microRNAs (miRNAs) (Figure 
1F). miR-539 directly binds the 3’ untranslated region of SPAG5 mRNAs and downregulates 
protein expression, resulting in the inhibition of prostate cancer cell proliferation, invasion, 
migration, as well as tumor growth and metastasis [5]. Similarly, miR-363-3p targets SPAG5 
and modulates its expression in hepatocellular cancer cell, affecting cell proliferation and 
migration via the SPAG5/CEP55/PIK3k/AKT axis [14]. In non-small cell lung cancer, miR-
1179 also regulates SPAG5 expression and suppresses cell growth and invasion by targeting 
SPAG5/AKT signaling [15]. These studies indicate that miRNAs play a critical role in 
controlling SPAG5 expression. 
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Concluding Remarks and Future Perspectives 
It has become clear that SPAG5 utilizes several mechanisms to exert its oncogenic effects. 
Given the essential role of SPAG5 in mitosis, SPAG5 antagonism may represent a novel 
strategy for anticancer therapy, especially in reversing chemoresistance. This is very promising 
considering that SPAG5 expression alters sensitivity to taxol in cervical cancer [4] and SPAG5 
knockdown results in enhanced tumor sensitivity to olaparib in triple-negative breast cancer 
[3]. Olaparib, as a PARP inhibitor for cancer therapy, relies on an exploitation of the defective 
DNA damage repair mechanism due to mutations and epigenetic changes of HR genes 
including BRCA1/2. SPAG5 antagonism may improve the efficacy of olaparib because SPAG5 
knockdown increased S-phase cell population and decreased the expression of DNA repair 
proteins RAD51 and BRCA1/2 [3]. 
One obstacle that prevents the use of SPAG5 as a drug target is its intracellular 
localization and lack of enzymatic activity, which makes it difficult to use antibodies or 
catalytical activity inhibitors to neutralize the function of SPAG5. Although antibodies and 
small molecular inhibitors dominate the approved drugs, there are many novel approaches to 
making intracellular proteins druggable. They include small peptide inhibitors, siRNAs and 
miRNAs, which can penetrate the membrane barriers. Moreover, antibodies against 
intracellular proteins may be internalized into cells by normal and pathological processes, even 
by direct delivery using various technologies including nanoparticle carriers. Future 
perspectives thus include the development of anti-SPAG5 therapeutic agents and effective 
delivery of them into cancer cells. 
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Table 1. SPAG5 copy number gain and amplification in cancer. Data were extracted from 
the COSMIC cancer database (https://cancer.sanger.ac.uk/cosmic).  
Cancer SPAG5 copy number gain SPAG5 overexpression 
Percentage (%) Cases (n) Percentage (%) Cases (n) 
Adrenal gland  - 7.59 79 




 - 9.33 697 
Cervix  - 3.58 307 
Endometrium 0.34 586 11.96 602 
Hematopoietic 
and lymphoid 
 - 8.6 221 
Kidney  - 11.17 600 
Large intestine 0.42 717 5.74 610 
Liver 0.45 663 5.9 373 
Lung 0.3 1006 10.89 1019 
Esophagus 0.2 510 10.4 125 
Ovary 1.02 684 2.63 266 
Pancreas  - 7.26 179 
Prostate  - 10.84 498 
Skin 0.17 587 5.92 473 
Soft tissue  - 9.13 263 
Stomach 0.64 472 7.72 285 
Thymus 0.81 124  - 




0.19 520 7.85 522 























































































































































Figure 1. Current understanding of SPAG5 signaling in cancer. (A) Sperm associated antigen 5 (SPAG5) 
is involved in the regulation of mammalian target of rapamycin complex 1 (mTORC1). Upon oxidative stress, 
SPAG5 and stress granules (SG) complex coupled with downregulated tuberous sclerosis proteins 1 and 2 
(TSC1-TSC2) lead to a balanced activity of mTORC1. Hyperactivation of mTORC1 causes apoptosis whereas 
a balanced mTORC1 activity promotes cell survival under stress. SPAG5 also prevents cancer cells from 
undergoing apoptosis by inhibiting p53. (B) SPAG5 is implicated in the expression of Wnt3. β-catenin, which 
is mediated by Wnt3, interacts with T cell factor (TCF) and promotes the transcription of oncogenes that 
regulate progression, metastasis and chemoresistance of cancer cells. (C) Binding of SPAG5 to centrosome 
protein 55 (Cep55) activates PI3K/AKT/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian 
target of rapamycin) signaling, which is related to cancer cell progression, metastasis, and chemoresistance. 
(D) Scavenger receptor class A member 5 (SCARA5) is an anti-oncogene that suppresses progression and 
metastasis of cancer. Upregulation of SPAG5 may thus promote the proliferation and metastasis of cancer 
cells by inhibiting SCARA5 through Wnt/β-catenin/TCF4 axis. (E) c-MYC is a crucial oncogenic 
transcription factor mediating gene transcription that is involved in multiple cellular mechanisms, including 
enhanced cell proliferation and reduced apoptosis. SPAG5 facilitates these processes by interacting with c-
MYC binding protein (MYCBP). SPAG5 also confers resistance to olaparib by either upregulating the DNA 
repair proteins RAD51, BRCA1 and BRCA2 or shortening the S-phase duration in which the olaparib-induced 
DNA lesions occur. (F) MicroRNAs (miRNAs) are small, highly conserved non-coding RNA molecules, some 
of which may repress cancer progression via SPAG5 in a given cancer type. Figures were created with 
BioRender.com. 
 
